| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = -$282,884 ) |
| | 2026 | 2025 | AQUALUNG THERAPEUTICS, CORP | 450 OCEAN DR APT 1205 | JUNO BEACH | FL | 33408-2051 | PALM BEACH | USA | R41HL180035 | Targeting eNAMPT-TLR4 signaling with the novel ALT-100 mAb to slow IPF progression | 000 | 1 | NIH | 1/30/2026 | $0 |
| | 2026 | 2024 | AQUALUNG THERAPEUTICS, CORP | 450 OCEAN DR APT 1205 | JUNO BEACH | FL | 33408-2051 | PALM BEACH | USA | R42DK135208 | Targeting the eNAMPT/TLR4 pathway to reduce Inflammatory Bowel Disease severity | 000 | 3 | NIH | 12/10/2025 | -$97,663 |
| | 2026 | 2024 | AQUALUNG THERAPEUTICS, CORP | 450 OCEAN DR APT 1205 | JUNO BEACH | FL | 33408-2051 | PALM BEACH | USA | R44HL145930 | A Randomized Phase 2A Clinical Trial Pioneering the Utility of an eNAMPT-Reducing Therapy in ARDS/VILI: the PUERTA Trial | 000 | 5 | NIH | 3/20/2026 | -$185,221 |
|
| Issue Date FY: 2025 ( Subtotal = -$257,707 ) |
| | 2025 | 2025 | AQUALUNG THERAPEUTICS, CORP | 450 OCEAN DR APT 1205 | JUNO BEACH | FL | 33408-2051 | PALM BEACH | USA | R41HL180035 | Targeting eNAMPT-TLR4 signaling with the novel ALT-100 mAb to slow IPF progression | 000 | 1 | NIH | 9/17/2025 | $284,699 |
| | 2025 | 2024 | AQUALUNG THERAPEUTICS, CORP | 450 OCEAN DR APT 1205 | JUNO BEACH | FL | 33408-2051 | PALM BEACH | USA | R44HL145930 | A Randomized Phase 2A Clinical Trial Pioneering the Utility of an eNAMPT-Reducing Therapy in ARDS/VILI: the PUERTA Trial | 000 | 5 | NIH | 5/13/2025 | -$542,406 |
| | 2025 | 2022 | AQUALUNG THERAPEUTICS, CORP | 450 OCEAN DR APT 1205 | JUNO BEACH | FL | 33408-2051 | PALM BEACH | USA | R42HL164300 | Preclinical Development of a Novel eNAMPT-Neutralizing mAb for Pulmonary Hypertension | 000 | 1 | NIH | 2/25/2025 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $3,284,214 ) |
| | 2024 | 2024 | AQUALUNG THERAPEUTICS, CORP | 450 OCEAN DR APT 1205 | JUNO BEACH | FL | 33408-2051 | PALM BEACH | USA | R42HL164300 | Preclinical Development of a Novel eNAMPT-Neutralizing mAb for Pulmonary Hypertension | 000 | 3 | NIH | 7/31/2024 | $808,999 |
| | 2024 | 2024 | AQUALUNG THERAPEUTICS, CORP | 450 OCEAN DR APT 1205 | JUNO BEACH | FL | 33408-2051 | PALM BEACH | USA | R42DK135208 | Targeting the eNAMPT/TLR4 pathway to reduce Inflammatory Bowel Disease severity | 001 | 3 | NIH | 7/16/2024 | $975,215 |
| | 2024 | 2024 | AQUALUNG THERAPEUTICS, CORP | 450 OCEAN DR APT 1205 | JUNO BEACH | FL | 33408-2051 | PALM BEACH | USA | R44HL145930 | A Randomized Phase 2A Clinical Trial Pioneering the Utility of an eNAMPT-Reducing Therapy in ARDS/VILI: the PUERTA Trial | 000 | 5 | NIH | 9/11/2024 | $1,500,000 |
| | 2024 | 2022 | AQUALUNG THERAPEUTICS, CORP | 450 OCEAN DR APT 1205 | JUNO BEACH | FL | 33408-2051 | PALM BEACH | USA | R42HL152888 | eNamptorTM: A Humanized mAb To Reduce the Severity of Radiation Pneumonitis and Fibrosis | 000 | 3 | NIH | 1/19/2024 | $0 |
| | 2024 | 2022 | AQUALUNG THERAPEUTICS, CORP | 450 OCEAN DR APT 1205 | JUNO BEACH | FL | 33408-2051 | PALM BEACH | USA | R41HL164154 | Targeting the P Selectin Pathway to Improve ARDS Survival | 000 | 1 | NIH | 4/9/2024 | $0 |
| | 2024 | 2022 | AQUALUNG THERAPEUTICS, CORP | 450 OCEAN DR APT 1205 | JUNO BEACH | FL | 33408-2051 | PALM BEACH | USA | R42DK135208 | Targeting the eNAMPT/TLR4 pathway to reduce Inflammatory Bowel Disease severity | 000 | 1 | NIH | 7/11/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $3,284,215 ) |
| | 2023 | 2023 | AQUALUNG THERAPEUTICS, CORP | 450 OCEAN DR APT 1205 | JUNO BEACH | FL | 33408-2051 | PALM BEACH | USA | R42HL164300 | Preclinical Development of a Novel eNAMPT-Neutralizing mAb for Pulmonary Hypertension | 001 | 2 | NIH | 9/19/2023 | $809,000 |
| | 2023 | 2023 | AQUALUNG THERAPEUTICS, CORP | 450 OCEAN DR APT 1205 | JUNO BEACH | FL | 33408-2051 | PALM BEACH | USA | R42DK135208 | Targeting the eNAMPT/TLR4 pathway to reduce Inflammatory Bowel Disease severity | 001 | 2 | NIH | 8/15/2023 | $975,215 |
| | 2023 | 2023 | AQUALUNG THERAPEUTICS, CORP | 450 OCEAN DR APT 1205 | JUNO BEACH | FL | 33408-2051 | PALM BEACH | USA | R44HL145930 | A Randomized Phase 2A Clinical Trial Pioneering the Utility of an eNAMPT-Reducing Therapy in ARDS/VILI: the PUERTA Trial | 000 | 4 | NIH | 9/8/2023 | $1,500,000 |
| | 2023 | 2022 | AQUALUNG THERAPEUTICS CORP. | 1790 EAST RIVER #205 | TUCSON | AZ | 85718-5957 | PIMA | USA | R42DK135208 | Targeting the eNAMPT/TLR4 pathway to reduce Inflammatory Bowel Disease severity | 000 | 1 | NIH | 1/27/2023 | $0 |
| | 2023 | 2022 | AQUALUNG THERAPEUTICS CORP. | 1790 EAST RIVER #205 | TUCSON | AZ | 85718-5957 | PIMA | USA | R42HL164300 | Preclinical Development of a Novel eNAMPT-Neutralizing mAb for Pulmonary Hypertension | 000 | 1 | NIH | 3/31/2023 | $0 |
| | 2023 | 2021 | AQUALUNG THERAPEUTICS, CORP | 450 OCEAN DR APT 1205 | JUNO BEACH | FL | 33408-2051 | PALM BEACH | USA | R42HL145930 | Novel Therapeutic Antibody Targeting of Extracellular NAMPT in Ventilator-Induced Lung Injury (VILI) | 000 | 3 | NIH | 11/10/2022 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $1,788,459 ) |
| | 2022 | 2022 | AQUALUNG THERAPEUTICS CORP. | 1790 EAST RIVER #205 | TUCSON | AZ | 85718-5957 | PIMA | USA | R42DK135208 | Targeting the eNAMPT/TLR4 pathway to reduce Inflammatory Bowel Disease severity | 000 | 1 | NIH | 9/19/2022 | $269,233 |
| | 2022 | 2022 | AQUALUNG THERAPEUTICS CORP. | 1790 EAST RIVER #205 | TUCSON | AZ | 85718-5957 | PIMA | USA | R42HL164300 | Preclinical Development of a Novel eNAMPT-Neutralizing mAb for Pulmonary Hypertension | 000 | 1 | NIH | 8/29/2022 | $259,613 |
| | 2022 | 2022 | AQUALUNG THERAPEUTICS CORP. | 1790 EAST RIVER #205 | TUCSON | AZ | 85718-5957 | PIMA | USA | R41HL164154 | Targeting the P Selectin Pathway to Improve ARDS Survival | 000 | 1 | NIH | 9/22/2022 | $259,613 |
| | 2022 | 2022 | AQUALUNG THERAPEUTICS CORP. | 1790 EAST RIVER #205 | TUCSON | AZ | 85718-5957 | PIMA | USA | R42HL152888 | eNamptorTM: A Humanized mAb To Reduce the Severity of Radiation Pneumonitis and Fibrosis | 000 | 3 | NIH | 5/30/2022 | $1,000,000 |
| | 2022 | 2020 | AQUALUNG THERAPEUTICS CORP. | 1790 EAST RIVER #205 | TUCSON | AZ | 85718-5957 | PIMA | USA | R41HD101202 | Extracellular NAMPT is a Novel Therapeutic Target in Chorioamnionitis-Related Prematurity (ChorP) | 000 | 1 | NIH | 2/22/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $1,750,000 ) |
| | 2021 | 2021 | AQUALUNG THERAPEUTICS CORP. | 1790 EAST RIVER #205 | TUCSON | AZ | 85718-5957 | PIMA | USA | R42HL145930 | Novel Therapeutic Antibody Targeting of Extracellular NAMPT in Ventilator-Induced Lung Injury (VILI) | 000 | 3 | NIH | 4/23/2021 | $750,000 |
| | 2021 | 2021 | AQUALUNG THERAPEUTICS CORP. | 1790 EAST RIVER #205 | TUCSON | AZ | 85718-5957 | PIMA | USA | R42HL152888 | eNamptorTM: A Humanized mAb To Reduce the Severity of Radiation Pneumonitis and Fibrosis | 000 | 2 | NIH | 6/1/2021 | $1,000,000 |
| | 2021 | 2021 | AQUALUNG THERAPEUTICS CORP. | 1790 EAST RIVER #205 | TUCSON | AZ | 85718-5957 | PIMA | USA | R42HL152888 | eNamptorTM: A Humanized mAb To Reduce the Severity of Radiation Pneumonitis and Fibrosis | 002 | 2 | NIH | 7/22/2021 | $1 |
| | 2021 | 2020 | AQUALUNG THERAPEUTICS CORP. | 4425 N HACIENDA DEL SOL ROAD | TUCSON | AZ | 85718-6617 | PIMA | USA | R41HD101202 | Extracellular NAMPT is a Novel Therapeutic Target in Chorioamnionitis-Related Prematurity (ChorP) | 000 | 1 | NIH | 10/15/2020 | $0 |
| | 2021 | 2020 | AQUALUNG THERAPEUTICS CORP. | 1790 EAST RIVER #205 | TUCSON | AZ | 85718-5957 | PIMA | USA | R42HL152888 | eNamptorTM: A Humanized mAb To Reduce the Severity of Radiation Pneumonitis and Fibrosis | 001 | 1 | NIH | 7/22/2021 | -$1 |
| | 2021 | 2019 | AQUALUNG THERAPEUTICS CORP. | 1790 EAST RIVER #205 | TUCSON | AZ | 85718-5957 | PIMA | USA | R41HL147769 | The CRIT-ICU Biomarker Panel for Stratification of Mortality Risk in ARDS Patients | 002 | 1 | NIH | 7/7/2021 | $0 |
| | 2021 | 2019 | AQUALUNG THERAPEUTICS CORP. | 1790 EAST RIVER #205 | TUCSON | AZ | 85718-5957 | PIMA | USA | R41HL147769 | The CRIT-ICU Biomarker Panel for Stratification of Mortality Risk in ARDS Patients | 001 | 1 | NIH | 5/12/2021 | $225,000 |
| | 2021 | 2019 | AQUALUNG THERAPEUTICS CORP. | 1790 EAST RIVER #205 | TUCSON | AZ | 85718-5957 | PIMA | USA | R42HL145930 | Novel Therapeutic Antibody Targeting of Extracellular NAMPT in Ventilator-Induced Lung Injury (VILI) | 001 | 1 | NIH | 6/25/2021 | $0 |
| | 2021 | 2019 | AQUALUNG THERAPEUTICS CORP. | 1790 EAST RIVER #205 | TUCSON | AZ | 85718-5957 | PIMA | USA | R41HL147769 | The CRIT-ICU Biomarker Panel for Stratification of Mortality Risk in ARDS Patients | 000 | 1 | NIH | 2/19/2021 | -$225,000 |
|
| Issue Date FY: 2020 ( Subtotal = $1,315,097 ) |
| | 2020 | 2020 | AQUALUNG THERAPEUTICS CORP. | 4425 N HACIENDA DEL SOL ROAD | TUCSON | AZ | 85718-6617 | PIMA | USA | R41HD101202 | Extracellular NAMPT is a Novel Therapeutic Target in Chorioamnionitis-Related Prematurity (ChorP) | 000 | 1 | NIH | 9/18/2020 | $265,096 |
| | 2020 | 2020 | AQUALUNG THERAPEUTICS CORP. | 4425 N HACIENDA DEL SOL ROAD | TUCSON | AZ | 85718-6617 | PIMA | USA | R42HL152888 | eNamptorTM: A Humanized mAb To Reduce the Severity of Radiation Pneumonitis and Fibrosis | 000 | 1 | NIH | 5/27/2020 | $300,001 |
| | 2020 | 2020 | AQUALUNG THERAPEUTICS CORP. | 4425 N HACIENDA DEL SOL ROAD | TUCSON | AZ | 85718-6617 | PIMA | USA | R42HL145930 | Novel Therapeutic Antibody Targeting of Extracellular NAMPT in Ventilator-Induced Lung Injury (VILI) | 001 | 2 | NIH | 5/12/2020 | $750,000 |
| | 2020 | 2019 | AQUALUNG THERAPEUTICS CORP. | 4425 N HACIENDA DEL SOL ROAD | TUCSON | AZ | 85718-6617 | PIMA | USA | R42HL145930 | Novel Therapeutic Antibody Targeting of Extracellular NAMPT in Ventilator-Induced Lung Injury (VILI) | 000 | 1 | NIH | 5/11/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $450,000 ) |
| | 2019 | 2019 | AQUALUNG THERAPEUTICS CORP. | 4425 N HACIENDA DEL SOL ROAD | TUCSON | AZ | 85718-6617 | PIMA | USA | R42HL145930 | Novel Therapeutic Antibody Targeting of Extracellular NAMPT in Ventilator-Induced Lung Injury (VILI) | 000 | 1 | NIH | 5/25/2019 | $225,000 |
| | 2019 | 2019 | AQUALUNG THERAPEUTICS CORP. | 4425 N HACIENDA DEL SOL ROAD | TUCSON | AZ | 85718-6617 | PIMA | USA | R41HL147769 | The CRIT-ICU Biomarker Panel for Stratification of Mortality Risk in ARDS Patients | 000 | 1 | NIH | 8/8/2019 | $225,000 |
|
|
